Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 8/20 | 0.33 |
| ▸ | AR | P10275 | 3/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2395852 | 0.82 | PGR (0.44) | NR3C1PGRARNR3C2 | |
| SCHEMBL2541110 | 0.81 | PGR (0.40) | NR3C1PGRAR | |
| SCHEMBL1325156 | 0.80 | NR3C1 (0.38) | NR3C1ALDH1A1MAPTHPGDHTT | |
| SCHEMBL17667953 | 0.80 | NR3C1 (0.47) | NR3C1ALDH1A1MAPTHPGDHTT | |
| SCHEMBL2544665 | 0.79 | MAPT (0.40) | NR3C1ALDH1A1MAPTHPGDHTT | |
| SCHEMBL1779383 | 0.79 | NR3C1 (0.35) | NR3C1ALDH1A1MAPTHPGDHTT | |
| SCHEMBL2393572 | 0.78 | KDM4E (0.41) | NR3C1ALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL4428816 | 0.78 | MAPT (0.44) | NR3C1ALDH1A1MAPTHPGDHTT | |
| SCHEMBL17667944 | 0.76 | MAPT (0.39) | NR3C1ALDH1A1MAPTHTTNPSR1 | |
| SCHEMBL2346391 | 0.76 | MAPT (0.41) | NR3C1ALDH1A1MAPTHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426406-B2 | Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-23 | — | — | US | disclosed |
| US-20110118260-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 2,2,4-TRIMETHYL-6-PHENYL-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING SUBSTITUTED OXY GROUP | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118260-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 2,2,4-TRIMETHYL-6-PHENYL-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING SUBSTITUTED OXY GROUP | NR3C1, NR3C2, MC2R | NR3C1 1/4885ALDH1A1 3334/4885MAPT 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.